Study Links RSV Vaccination to Lower Mortality in Older Heart Failure Patients

Respiratory syncytial virus vaccination is linked to significantly lower all-cause mortality among older adults suffering from heart failure, according to a recent multicenter analysis of electronic health records in the United States.

Researchers examined health outcomes for adults aged 60 and older with heart failure by comparing their respiratory syncytial virus vaccination status. Through propensity score matching, investigators analyzed 777 vaccinated patients alongside 777 unvaccinated patients who shared balanced baseline characteristics, including demographics, medication use, and existing health conditions. All-cause mortality was observed in 3.8 percent of the vaccinated group, compared with 11.1 percent of the unvaccinated individuals. Furthermore, vaccination was associated with a 49 percent lower hazard of death, yielding a hazard ratio of 0.51. Intensive care unit admissions were also notably lower among vaccinated patients at 2.7 percent, versus 5.8 percent for unvaccinated participants.

Despite the survival benefits, the study found no significant differences between the two cohorts regarding several other clinical measures. Respiratory failure occurred in 7.3 percent of vaccinated patients and 9.4 percent of unvaccinated patients, while inpatient or emergency visits were recorded at 29.9 percent and 35.1 percent, respectively. Additionally, rates of stroke, myocardial infarction, and heart failure exacerbations remained similar across both groups. Overall healthcare utilization proved significantly higher in the vaccinated cohort with a hazard ratio of 1.85, which investigators suggested might indicate greater engagement with nonacute and outpatient care among individuals who opted for the vaccination.

Because the observational design could not fully account for unmeasured factors such as heart failure severity, frailty, functional status, socioeconomic position, or the completeness of guideline-directed therapy, the study authors characterized their findings as hypothesis-generating rather than definitive proof of a causal survival benefit. Nevertheless, researchers concluded that these results support further evaluation of respiratory syncytial virus vaccination as a potential strategy to reduce severe clinical outcomes in this high-risk population.